Benzinga's Top Upgrades, Downgrades For August 18, 2020

Upgrades

• Wedbush upgraded the previous rating for Best Buy Co Inc BBY from Neutral to Outperform. For the first quarter, Best Buy Co had an EPS of $0.67, compared to year-ago quarter EPS of $1.02. At the moment, the stock has a 52-week-high of $111.39 and a 52-week-low of $48.10. Best Buy Co closed at $110.77 at the end of the last trading period.
• Cantor Fitzgerald upgraded the previous rating for Curaleaf Holdings Inc CURLF from Neutral to Overweight. Curaleaf Holdings earned $0.03 in the first quarter, compared to $0.02 in the year-ago quarter. The current stock performance of Curaleaf Holdings shows a 52-week-high of $9.66 and a 52-week-low of $2.54. Moreover, at the end of the last trading period, the closing price was at $9.43.
• For Barings BDC Inc BBDC, Keefe, Bruyette & Woods upgraded the previous rating of Market Perform to the current rating Outperform. For the second quarter, Barings BDC had an EPS of $0.14, compared to year-ago quarter EPS of $0.15. At the moment, the stock has a 52-week-high of $10.59 and a 52-week-low of $4.67. Barings BDC closed at $8.30 at the end of the last trading period.
•  

Downgrades

• According to Argus Research, the prior rating for Howmet Aerospace Inc HWM was changed from Buy to Hold. Howmet Aerospace earned $0.12 in the second quarter, compared to $0.58 in the year-ago quarter. At the moment, the stock has a 52-week-high of $18.99 and a 52-week-low of $9.87. Howmet Aerospace closed at $17.35 at the end of the last trading period.
• For AMAG Pharmaceuticals Inc AMAG, Barclays downgraded the previous rating of Overweight to the current rating Equal-Weight. AMAG Pharmaceuticals earned $0.57 in the second quarter, compared to $1.14 in the year-ago quarter. The stock has a 52-week-high of $13.53 and a 52-week-low of $4.41. At the end of the last trading period, AMAG Pharmaceuticals closed at $10.89.
• Oppenheimer downgraded the previous rating for Intercontinental Exchange Inc ICE from Outperform to Perform. For the second quarter, Intercontinental Exchange had an EPS of $1.07, compared to year-ago quarter EPS of $0.94. The current stock performance of Intercontinental Exchange shows a 52-week-high of $104.30 and a 52-week-low of $63.51. Moreover, at the end of the last trading period, the closing price was at $104.07.
• For Montage Resources Corp MR, Johnson Rice downgraded the previous rating of Buy to the current rating Hold. At the moment, the stock has a 52-week-high of $8.30 and a 52-week-low of $1.99. Montage Resources closed at $5.51 at the end of the last trading period.
• According to Citigroup, the prior rating for Nabors Industries Ltd NBR was changed from Neutral to Sell. For the second quarter, Nabors Industries had an EPS of $14.45, compared to year-ago quarter EPS of $0.41. At the moment, the stock has a 52-week-high of $87.00 and a 52-week-low of $0.20. Nabors Industries closed at $46.45 at the end of the last trading period.
• For Unity Biotechnology Inc UBX, Morgan Stanley downgraded the previous rating of Overweight to the current rating Equal-Weight. Unity Biotechnology earned $0.38 in the second quarter, compared to $0.56 in the year-ago quarter. At the moment, the stock has a 52-week-high of $15.44 and a 52-week-low of $4.05. Unity Biotechnology closed at $4.15 at the end of the last trading period.
• Morgan Stanley downgraded the previous rating for Vonage Holdings Corp VG from Overweight to Equal-Weight. Vonage Hldgs earned $0.04 in the second quarter, compared to $0.08 in the year-ago quarter. The current stock performance of Vonage Hldgs shows a 52-week-high of $13.66 and a 52-week-low of $4.18. Moreover, at the end of the last trading period, the closing price was at $11.77.
• SVB Leerink downgraded the previous rating for Principia Biopharma Inc PRNB from Outperform to Market Perform. The current stock performance of Principia Biopharma shows a 52-week-high of $99.38 and a 52-week-low of $25.35. Moreover, at the end of the last trading period, the closing price was at $99.25.

Initiations

• With a current rating of Outperform, Wedbush initiated coverage on Inozyme Pharma Inc INZY. The price target seems to have been set at $35.00 for Inozyme Pharma. The current stock performance of Inozyme Pharma shows a 52-week-high of $31.27 and a 52-week-low of $17.25. Moreover, at the end of the last trading period, the closing price was at $29.00.
• Needham initiated coverage on Nurix Therapeutics Inc NRIX with a Buy rating. The price target for Nurix Therapeutics is set to $35.00. The current stock performance of Nurix Therapeutics shows a 52-week-high of $27.64 and a 52-week-low of $15.21. Moreover, at the end of the last trading period, the closing price was at $27.00.
• Brookline Capital initiated coverage on 9 Meters Biopharma Inc NMTR with a Buy rating. The price target for 9 Meters Biopharma is set to $5.00. 9 Meters Biopharma earned $0.57 in the second quarter, compared to $0.13 in the year-ago quarter. The stock has a 52-week-high of $0.82 and a 52-week-low of $0.44. At the end of the last trading period, 9 Meters Biopharma closed at $0.56.
• JP Morgan initiated coverage on ITeos Therapeutics Inc ITOS with an Overweight rating. The price target for ITeos Therapeutics is set to $40.00. At the moment, the stock has a 52-week-high of $32.98 and a 52-week-low of $17.50. ITeos Therapeutics closed at $32.92 at the end of the last trading period.
• With a current rating of Buy, Citigroup initiated coverage on Digital Media Solutions Inc DMS. The price target seems to have been set at $12.00 for Digital Media Solutions. At the moment, the stock has a 52-week-high of $10.66 and a 52-week-low of $6.75. Digital Media Solutions closed at $8.41 at the end of the last trading period.
• With a current rating of Buy, B of A Securities initiated coverage on Annexon Inc ANNX. The price target seems to have been set at $33.00 for Annexon. The stock has a 52-week-high of $29.71 and a 52-week-low of $15.33. At the end of the last trading period, Annexon closed at $26.55.
• Wells Fargo initiated coverage on Voya Financial Inc VOYA with an Overweight rating. The price target for Voya Finl is set to $62.00. For the second quarter, Voya Finl had an EPS of $1.09, compared to year-ago quarter EPS of $1.52. The stock has a 52-week-high of $63.81 and a 52-week-low of $29.75. At the end of the last trading period, Voya Finl closed at $51.22.
• B of A Securities initiated coverage on Inozyme Pharma Inc INZY with a Buy rating. The price target for Inozyme Pharma is set to $33.00. At the moment, the stock has a 52-week-high of $31.27 and a 52-week-low of $17.25. Inozyme Pharma closed at $29.00 at the end of the last trading period.
• For Annexon Inc ANNX, Cowen & Co. initiated coverage, by setting the current rating at Outperform. The current stock performance of Annexon shows a 52-week-high of $29.71 and a 52-week-low of $15.33. Moreover, at the end of the last trading period, the closing price was at $26.55.
• With a current rating of Overweight, Piper Sandler initiated coverage on ITeos Therapeutics Inc ITOS. The price target seems to have been set at $50.00 for ITeos Therapeutics. The current stock performance of ITeos Therapeutics shows a 52-week-high of $32.98 and a 52-week-low of $17.50. Moreover, at the end of the last trading period, the closing price was at $32.92.
• Piper Sandler initiated coverage on Seres Therapeutics Inc MCRB with an Overweight rating. The price target for Seres Therapeutics is set to $40.00. In the second quarter, Seres Therapeutics showed an EPS of $0.28, compared to $0.24 from the year-ago quarter. At the moment, the stock has a 52-week-high of $33.00 and a 52-week-low of $2.52. Seres Therapeutics closed at $26.16 at the end of the last trading period.
• Needham initiated coverage on Personalis Inc PSNL with a Buy rating. The price target for Personalis is set to $25.00. For the second quarter, Personalis had an EPS of $0.29, compared to year-ago quarter EPS of $0.89. The stock has a 52-week-high of $23.00 and a 52-week-low of $4.27. At the end of the last trading period, Personalis closed at $21.72.